Mary Del Brady
Chair and CEO 

Mary Del Brady is an entrepreneur whose 30 years of professional experience includes the founding and ownership of several companies in the services and biotechnology industries.   She has also held an executive role within an academic health system and has served as director/advisor for numerous not-for-profit and for-profit boards.

Since 1997, Mary Del has helped to launch several biotechnology companies including TissueInformatics Inc ("TII"), a bioinformatic s company that developed software tools to capture, analyze and mine data within human tissue.  TII was subsequently acquired by Clinical Data (NASDAQ: CLDA).  She was the founding CEO of RedPath Integrated Pathology, Inc., a genomics-based diagnostic company with facilitates early and accurate cancer diagnosis.  She led the company through its first 5 critical years - winning vital Medicare and Blue Cross reimbursement and successfully commercializing its flagship PathFinderTG® testing services with year over year revenue increases and sales into more than 100 hospitals and institutions in the United States. The Company’s success was recognized nationally in November 2008 with the Frost & Sullivan Emerging Company Award for Best Practices.

Mary Del is co-Founder and Director of ThermalTherapeuticsSystems Inc., a medical device company that is developing a next stage protable perfusion device with special applications in the oncology field, and she is Chairman of the Board of iNTELOMED, Inc., a medical device company that is developing superior markers for cardiovascular health. 

A business owner and advocate who launched her first start up at the age of 24, Mary Del has served in a wide variety of leadership capacities and has been the recipient of numerous awards including the E & Y Entrepreneur of the Year award and the University of Pittsburgh’s Katz Graduate School of Business Distinguished Alumnus Award. 





 Javier F. Torres-Roca, M.D.
Co-Founder and Chief Scientific Officer

Dr. Javier F. Torres-Roca is Co-Founder of CvergenX, Inc., a biotechnology company committed to individualizing radiation therapy for cancer patients.  He obtained his medical degree from the University of Puerto Rico and subsequently performed post-doctoral training in immunology and molecular biology in the laboratories of Nobel Laureate Professor Luc Montagnier at the Institut Pasteur and Dr. Irving Weismann and Dr. Leonard Herzenberg at Stanford University.  He completed his clinical training in radiation oncology at the University of California.  Since 2002 he has been clinical faculty at the Moffitt Cancer Center with a sub-specialty in urological malignancies.  His research is currently funded by the National Cancer Institute, the Department of Defense, and the State of Florida.  He is a board certified radiation oncologist by The American Board of Radiology.



 
Steven A. Eschrich, Ph.D.
Co-Founder

Dr. Eschrich is an Assistant Member in the Department of Biomedical Informatics and Scientific Director of the Biomedical Informatics Core at the Moffitt Cancer Center. Dr. Eschrich received his Ph.D. from the University of South Florida in 2003, with an emphasis on developing scalable machine learning algorithms for bioinformatics applications. Dr. Eschrich has extensive experience in gene expression microarray analysis in translational cancer research. He has been involved in microarray studies involving tumor diagnosis from specimens of unknown origin; prediction of patient prognosis in colorectal cancer and a multi-institutional project in lung cancer; developing predictors of response to chemotherapy such as response to Velcade in multiple myeloma; developing a systems-biology based model for radiotherapy; and developing a model of chemotherapy resistance from cell line data. He has also developed various software packages for processing Affymetrix microarray data. He has been involved a number of proteomics-based projects, including developing a 2D-gel based predictor of tumor diagnosis and developing a signaling network based on phosphoproteomics from mass spectrometry. He recently developed an in silico tool for predicting the detection of a population of peptides using different digestion techniques.

3802 Spectrum Boulevard, Suite 149
Tampa, FL  33612
412.889.2849

info@cvergenx.com